血浆p-tau217作为阿尔茨海默病临床试验终点的评估
该回顾性研究纳入4个队列共716人,评估血浆p-tau217在早期阿尔茨海默病临床试验中作为主要终点的纵向表现。Aβ阳性认知未损与认知受损组的年变化率相似,效应量分别为0.64和0.62;选择中间Aβ水平(Centiloid 20-40)者效应量更高,所需样本量更小。
要点
- Aβ阳性者血浆p-tau217年变化率在认知未损与认知受损组间相似。
- 检测25%药物效应所需每组样本量:认知未损610、认知受损664。
- 选择Centiloid 20-40者效应量更高,所需样本量降至342与492。
核心结论
- 血浆p-tau217变化可作为针对Aβ病理的认知未损或认知受损人群临床试验的稳健终点。
研究设计与样本
- 回顾性研究,纳入ADNI、BICWALZS、MYHAT-NI和WRAP共4个队列的716名参与者。
- 纳入者至少有2个时间点的血浆p-tau217测量,并有基线Aβ PET影像和临床评估。
- 采用线性混合效应模型评估血浆p-tau217轨迹与临床或生物标志物结局的关联。
主要发现
- Aβ阳性认知未损组血浆p-tau217年变化率为0.07 pg/mL/y(SD=0.11),认知受损组为0.08 pg/mL/y(SD=0.13)。
- Aβ阳性认知未损与认知受损组的效应量分别为0.64和0.62。
- 检测25%药物效应(80%把握度,0.05检验水准)所需每组最小样本量:认知未损610、认知受损664。
- 选择中间Aβ水平(Centiloid 20-40)者效应量更高(认知未损0.85、认知受损0.72),所需每组样本量降至342与492。
关键数值与推荐
- 效应量定义为血浆p-tau217年均变化率除以其标准差。
- 样本量计算设定为检测25%药物效应、80%把握度、0.05检验水准。
临床怎么用
- 可将血浆p-tau217作为早期AD临床试验的主要终点候选指标。
- 入组时选择中间Aβ水平(Centiloid 20-40)人群可提高效应量并减少所需样本量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Plasma phosphorylated tau 217 (p-tau217) levels have been shown to parallel neurofibrillary tangle and cognitive decline over time. Although recent clinical trials have demonstrated exploratory drug effects on plasma p-tau217, little is known about plasma p-tau217 effect size and performance as an endpoint in Alzheimer disease (AD) clinical trials. Therefore, the objective of this study was to assess the longitudinal performance and potential utility of plasma p-tau217 as a primary endpoint in early-stage AD clinical trials. METHOD: This retrospective study included participants from 4 cohorts: ADNI (a multisite observational study), BICWALZS (a South Korean memory clinic-based cohort), MYHAT-NI (a Southwestern Pennsylvania population-based cohort), and WRAP (older adults at risk for AD). Eligible participants had plasma p-tau217 measurements at least at 2 timepoints, along with baseline Aβ PET imaging and clinical assessments. Linear mixed-effects models were used to assess associations between plasma p-tau217 trajectories and clinical or biomarker outcomes. Effect size was defined as the mean annual rate of change in p-tau217 divided by its standard deviation. We calculated the sample size required for a hypothetical clinical trial designed to detect a 25% drug effect with 80% power at a 0.05 test level. RESULTS: A total of 716 individuals were included in the analysis: 413 cognitively unimpaired (CU) participants (58.6% female; mean age = 70.6 years, SD = 7.9) and 303 cognitively impaired (CI) participants (54.7% female; mean age = 73.2 years, SD = 7.4). In Aβ-positive individuals, the annual rate of change in plasma p-tau217 was similar between CU (0.07 pg/mL/y, SD = 0.11) and CI (0.08 pg/mL/y, SD = 0.13) groups. Effect size was 0.64 and 0.62 in CU and CI Aβ-positive individuals, respectively. The minimum sample size required per study group to detect a 25% drug effect was 610 for the CU Aβ-positive and 664 for the CI Aβ-positive group. Notably, selecting individuals with intermediate Aβ levels (Centiloid 20-40) yielded higher effect sizes (CU: 0.85; CI: 0.72), which reduced the required sample sizes per study group to 342 for CU and 492 for CI. DISCUSSION: Our findings support that changes in plasma p-tau217 represent a robust endpoint for clinical trials targeting CU or CI individuals with Aβ pathology.
引用
- Ferreira PCL, Bellaver B, Povala G, et al. Evaluating Plasma p-tau217 as an Endpoint for Alzheimer Disease Clinical Trials. Neurology. 2025. PMID: 41364889. doi:10.1212/WNL.0000000000214441
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。